Skip to main content
release_alert
Welcome to the new Scholars 3.0! Read about new features and let us know what you think.
cancel
Journal cover image

The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).

Publication ,  Journal Article
Morrison, VA; McCall, L; Muss, HB; Jatoi, A; Cohen, HJ; Cirrincione, CT; Ligibel, JA; Lafky, JM; Hurria, A
Published in: J Geriatr Oncol
May 2018

OBJECTIVE: Actual weight-based (AWB) chemotherapy dosing is recommended for obese patients in the 2012 ASCO Clinical Practice Guideline. CALGB 49907, which utilized ABW-based adjuvant chemotherapy dosing, was a phase 3 trial in women age≥65years with early stage breast cancer, providing the opportunity to examine impact of such dosing on toxicities and outcome in older patients with breast cancer. MATERIALS AND METHODS: Adverse event data were available for 615 of 633 enrolled patients. Objectives were to assess grade≥3 hematologic/non-hematologic toxicities by treatment arm, age, study entry BSA/BMI, and relapse-free (RFS) and overall survival (OS) by BSA/BMI. RESULTS: The 615 patients were sub-grouped by BSA (quartiles) and standard BMI categories, with BMI underweight/normal weight categories combined. Overall, grade≥3 non-hematologic and hematologic toxicities occurred in 39.8% and 28.3% of patients, respectively. There were no significant differences in grade≥3 toxicities among BSA quartiles. However, more grade≥3 hematologic toxicities occurred in the underweight/normal weight BMI subgroup compared to overweight/obese subgroups (p=0.048). Type of chemotherapy and age had no impact on toxicity occurrence by BSA/BMI categories. RFS was superior in the 25th-50th BSA percentile patients in univariate analysis (p=0.042), as was OS in both univariate and multivariate analyses (p=0.007, p=0.009, respectively). No differences in RFS or OS were found by BMI categories. CONCLUSION: Obesity was not correlated with adverse relapse or survival outcome, and grade≥3 toxicities were not greater with ABW-based dosing. This supports safety and efficacy of ABW-based dosing as per the 2012 ASCO clinical practice guideline. ClinicalTrials.gov Identifier: NCT00024102 (49907).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Geriatr Oncol

DOI

EISSN

1879-4076

Publication Date

May 2018

Volume

9

Issue

3

Start / End Page

228 / 234

Location

Netherlands

Related Subject Headings

  • Retrospective Studies
  • Outcome Assessment, Health Care
  • Obesity
  • Humans
  • Female
  • Dose-Response Relationship, Drug
  • Chemotherapy, Adjuvant
  • Breast Neoplasms
  • Body Size
  • Body Mass Index
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morrison, V. A., McCall, L., Muss, H. B., Jatoi, A., Cohen, H. J., Cirrincione, C. T., … Hurria, A. (2018). The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). J Geriatr Oncol, 9(3), 228–234. https://doi.org/10.1016/j.jgo.2017.11.007
Morrison, Vicki A., Linda McCall, Hyman B. Muss, Aminah Jatoi, Harvey J. Cohen, Constance T. Cirrincione, Jennifer A. Ligibel, Jacqueline M. Lafky, and Arti Hurria. “The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).J Geriatr Oncol 9, no. 3 (May 2018): 228–34. https://doi.org/10.1016/j.jgo.2017.11.007.
Journal cover image

Published In

J Geriatr Oncol

DOI

EISSN

1879-4076

Publication Date

May 2018

Volume

9

Issue

3

Start / End Page

228 / 234

Location

Netherlands

Related Subject Headings

  • Retrospective Studies
  • Outcome Assessment, Health Care
  • Obesity
  • Humans
  • Female
  • Dose-Response Relationship, Drug
  • Chemotherapy, Adjuvant
  • Breast Neoplasms
  • Body Size
  • Body Mass Index